Successful use of full-dose dexamethasone, high-dose cytarabine, and cisplatin as part of initial therapy in non-hodgkin and hodgkin lymphoma with severe hepatic dysfunction

Clinical Lymphoma and Myeloma

Volumn 9, Issue 2, 2009, Pages 167-170

  McCarthy, Jeanne ^a   Gopal, Ajay ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

Author keywords

Cholestasis; Liver disease; Motor neuropathy; Neutropenia; Rituximab

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; BURKITT LYMPHOMA; CANCER DIAGNOSIS; CANCER REGRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSE LARGE B CELL LYMPHOMA; DRUG EFFICACY; DRUG SAFETY; HODGKIN DISEASE; HUMAN; HYPERBILIRUBINEMIA; IMMUNOHISTOCHEMISTRY; INFECTION; LIVER BIOPSY; LIVER DYSFUNCTION; MALE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; THROMBOCYTOPENIA; LARGE CELL LYMPHOMA; LIVER DISEASE; METABOLISM; PROGNOSIS; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYTARABINE; DEXAMETHASONE; HODGKIN DISEASE; HUMANS; HYPERBILIRUBINEMIA; LIVER DISEASES; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; PROGNOSIS; TREATMENT OUTCOME;

EID: 67650654686     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.039     Document Type: Article

References (26)

1. Elias L, Portlock CS, Rosenberg SA. Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, Adriamycin, vincristine, and prednisone (CHOP). Cancer 1978; 42:1705-10.
2. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328:1002-6.
3. Ghobrial IM, Wolf RC, Pereira DL, et al. Therapeutic options in patients with lymphoma and severe liver dysfunction. Mayo Clin Proc 2004; 79:169-75.
4. Leeuwenburgh I, Lugtenburg EP, van Buuren HR, et al. Severe jaundice, due to vanishing bile duct syndrome, as presenting symptom of Hodgkin's lymphoma, fully reversible after chemotherapy. Eur J Gastroenterol Hepatol 2008; 20:145-7.
5. Vincristine Sulfate Injection [Package insert]. Irvine (CA): SICOR Pharmaceuticals, Inc.; 2003.
6. Adriamycin (DOXOrubicin HCl) for Injection USP [Package insert]. Bedford (OH): Bedford Laboratories; 2006.
7. Coiffier B. Treatment of non-Hodgkin's lymphoma: a look over the Past Decade. Clin Lymphoma Myeloma 2006; 7(suppl 1):S7-13.
8. Press OW, Livingston R, Mortimer J, et al. Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation. J Clin Oncol 1991; 9:423-31.
9. Crosbie OM, Crown JP, Nolan NP, et al. Resolution of paraneoplastic bile duct paucity following successful treatment of Hodgkin's disease. Hepatology 1997; 26:5-8.
10. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an Intergroup trial. J Clin Oncol 2003; 21:607-14.
11. Besson C, Canioni D, Lepage E, et al. Characteristics and outcome of diffuse large B-cell lymphoma in cepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte Programs. J Clin Oncol 2006; 24:953-60.
12. Law JK, Ho JK, Hoskins P, et al. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005; 46:1085-9.
13. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-39.
14. Rituxan (rituximab) injection for intravenous use [Package insert]. South San Francisco (CA): Genentech, Inc.; 2008.
15. Vinblastine Sulfate for Injection USP [Package insert]. Bedford (OH): Bedford Laboratories; 2001.
16. Danesi R, Fogli S, Gennari A, et al. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet 2002; 41:431-44.
17. Floyd J, Mirza I, Sachs B, et al. Hepatotoxicity of chemotherapy. Semin Oncol 2006; 33:50-67.
18. Asby E, Hagberg H, Kvalay S, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003; 101:3840-8.
19. Pangalis GA, Vassilakopoulos TP, Michalis E, et al. A randomized trial comparing intensified CNOP vs. CHOP in patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2003; 44:635-44.
20. Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71:117-22.
21. Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17:3776-85.
22. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP --an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12:1169-76.
23. Eklund JW, Trifilio S, Mulcahy MF. Chemotherapy dosing in the setting of liver dysfunction. Oncology (Williston Park) 2005; 19:1057-63.
24. Lam M, Ignoffo RJ. A guide to clinically relevant drug interactions in oncology. J Oncol Pharm Pract 2003; 9:45-85.
25. Cole DE, Balis FM, Grant N, et al. Pharmacokinetics (pk) and tolerance of infusional vincristine (vcr) for aggressive lymphomas indicate dose reductions for excretory organ dysfunction are not necessary. J Clin Oncol 2008; 26(15 suppl):124s (Abstract 2550).
26. Cole DE, Balis FM, Lowe ES, et al. Pharmacokinetics (pk) and tolerance of doxorubicin (dox) and etoposide (etop) during treatment of aggressive B-cell lymphomas indicate doses need not be routinely reduced for hepatic dysfunction. J Clin Oncol 2005; 23(16 suppl):578s (Abstract 6573).